Physician profile
Jason Pollock
NPI 1306917117
$2,209.07
in general payments reported to CMS, 2019-2025
28 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $308 · 2021: $310 · 2022: $382 · 2023: $361 · 2024: $321 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $634.92 | 2019-2023 | |
| Channel Medsystems, INC. | $193.99 | 2022-2023 | |
| Ascend Therapeutics US, LLC | $189.28 | 2023-2024 | |
| Astellas Pharma US INC | $160.91 | 2022-2024 | Veozah, Myrbetriq |
| Stryker Corporation | $134.43 | 2022-2025 | 1788 |
| Inari Medical, INC. | $113.64 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Organon LLC | $102.35 | 2022-2025 | Nexplanon |
| Boston Scientific Corporation | $87.85 | 2022-2025 | Bulkamid - Bulkamid Urethral Bulking Pack 2ml (Ous) |
| Daiichi Sankyo INC. | $78.98 | 2019-2021 | |
| Sage Therapeutics, LLC | $63.45 | 2025 | Zurzuvae |
| Medtronic, INC. | $52.42 | 2021-2025 | Intellis Adaptivestim |
| Supernus Pharmaceuticals, INC. | $48.03 | 2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $47.93 | 2019-2020 | |
| Duchesnay USA Incorporated | $32.25 | 2019 | |
| Merck Sharp & Dohme LLC | $28.78 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $28.73 | 2025 | Slynd |
| Mylan Pharmaceuticals INC. | $28.05 | 2021-2022 | |
| Avion Pharmaceuticals | $22.96 | 2021 | |
| Pfizer INC. | $22.44 | 2024 | |
| Lupin INC. | $21.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.02 | 2020 | |
| Mayne Pharma Commercial LLC | $15.73 | 2025 | |
| Coopersurgical, INC. | $14.98 | 2022 | |
| Conmed Corporation | $14.85 | 2024 | Airseal, Vcare |
| Ethicon US, LLC | $14.72 | 2019 | |
| Millicent US INC | $12.71 | 2023 | Intrarosa |
| Evofem Biosciences, INC. | $12.42 | 2020 | |
| Allergan, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Pollock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.